Living With Transfusion-Dependent Thalassemia: A Long Medical Journey

In the early months of life, a child who appeared healthy began showing signs that something was seriously wrong. At around 3 months of age, during a routine visit for polio drops, severe anemia was detected. Hemoglobin was critically low at nearly 3 g/dL, and the reticulocyte count was elevated at 11%, suggesting ongoing hemolysis and marrow stress.

At that stage, the diagnosis was unclear. Possibilities such as dyserythropoietic hemolytic anemia were considered. Initial sickling tests were negative. However, further hematological workup gradually pointed toward a severe hemoglobinopathy.

In July 2002, HPLC testing revealed:

HbF around 88.7%
HbA2 approximately 3.34%
Markedly reduced adult hemoglobin fractions

This pattern strongly suggested severe beta-thalassemia.

Soon afterward, the child required the first blood transfusion of about 150 mL. Unfortunately, this was not a one-time event. Recurrent severe anemia led to frequent transfusion dependence from infancy onward.

By December 2002, hepatosplenomegaly had already developed, reflecting massive extramedullary hematopoiesis and chronic hemolysis. In January 2003, peripheral smear findings showed:

anisocytosis,
target cells,
abnormal red cell morphology.

Interestingly, the mother’s peripheral smear also demonstrated target cells and anisocytosis, suggesting carrier status within the family.

As transfusions accumulated, iron overload became a major complication. In November 2003, iron chelation therapy was initiated. Ferritin levels progressively increased and reached approximately 6309 ng/mL by 2005, indicating severe systemic iron burden.

Bone marrow transplantation was advised as a potentially curative option. However, financial limitations made transplantation inaccessible — a harsh reality faced by many families dealing with chronic hematological disorders.

Chelation therapy continued with deferiprone (Kelfer), but treatment adherence became difficult due to toxicity and side effects. By 2007, the medication had to be avoided because of intolerance.

Over the years, chronic complications of transfusion-dependent thalassemia slowly emerged.

From 2008 onward, the patient began experiencing persistent leg pains, likely related to marrow expansion, metabolic bone disease, or iron overload effects. Despite prolonged illness, cardiac evaluation in 2015 through 2D echocardiography remained normal, offering some reassurance against severe iron-induced cardiomyopathy at that time.

In 2016, splenectomy was performed after years of splenomegaly and transfusion burden. Following surgery, vaccinations including Hib and pneumococcal vaccines were administered. Splenectomy altered the hematological profile significantly and introduced new long-term risks including infections, thrombocytosis, and immune dysregulation.

Chelation therapy with deferasirox continued, though ferritin levels remained persistently elevated:

Ferritin around 4005 ng/mL in 2017
Later fluctuating again above 5000 ng/mL

Endocrine complications also began appearing. Elevated TSH around 7 led to initiation of thyroxine replacement therapy, suggesting iron-overload–associated hypothyroidism.

In 2018, the patient developed lower respiratory tract infection with heart failure features and hepatomegaly, accompanied by neutrophilic leukocytosis. This episode highlighted the fragile balance between chronic anemia, iron toxicity, immune dysfunction, and recurrent infections in long-standing thalassemia.

Years later, definitive genetic confirmation was obtained. In 2022, molecular analysis demonstrated:

Homozygous IVS1-5 (G>C) mutation in the beta-globin gene

This mutation is a severe beta-plus thalassemia mutation commonly associated with transfusion-dependent disease in the Indian subcontinent.

The following years brought additional complications.

In 2023, recurrent headaches became prominent. During the same year, the patient sustained a left scapular body fracture, possibly reflecting chronic bone fragility associated with thalassemia-related metabolic bone disease and marrow expansion.

In 2025, a prolonged right foot abscess required antibiotics and repeated dressing for nearly five months. Chronic wounds and delayed healing can occur in patients with iron overload, immune dysfunction, nutritional deficiencies, and altered circulation.

During June 2025, a rash developed over the right lower lumbar region. Initially described as petechial, the history later suggested a bullous lesion that ruptured. Platelet counts showed marked fluctuations, creating diagnostic confusion.

Further concern arose in March 2026 when the patient was admitted with:

fever,
thrombocytopenia,
leukocytosis,
platelet counts around 78,000–85,000,
WBC counts as high as 37,500.

Doxycycline therapy led to resolution of fever, suggesting an infectious trigger, possibly rickettsial or atypical bacterial in origin.

However, platelet counts continued fluctuating dramatically afterward:

25,000,
38,000,
then nearly 1 lakh on other occasions.

A striking observation complicated the picture:

Platelet counts appeared very low in EDTA samples,
but finger-prick samples showed counts closer to 1.6 lakh.

This discrepancy strongly suggests EDTA-dependent pseudothrombocytopenia — a laboratory artifact where platelets clump inside EDTA tubes and falsely appear low on automated analyzers. Such phenomena are especially important to recognize in chronically transfused and splenectomized patients because misdiagnosis can lead to unnecessary panic, invasive testing, or inappropriate treatment.

Today, this journey reflects far more than a diagnosis of thalassemia.

It is a story of:

lifelong transfusion dependence,
iron overload,
financial barriers to curative therapy,
endocrine complications,
skeletal disease,
chronic infection risk,
immune alterations after splenectomy,
and the psychological burden of surviving a lifelong hematological disorder.

At the same time, it also reflects survival through decades of complex medical care, evolving therapies, and repeated medical crises.

Beta-thalassemia is not merely an anemia. In severe transfusion-dependent forms, it becomes a lifelong multisystem disease affecting nearly every organ system. This case demonstrates both the progress modern medicine has made and the enormous challenges that still remain for patients living with chronic inherited blood disorders.